Celgene, Agios extend collaboration as AG-221 impresses at ASH 2014
This article was originally published in Scrip
Agios Pharmaceuticals reached a new high of $107.30 on 8 December after the San Francisco-based developer of drugs targeting cancer metabolism said Celgene extended the companies' partnership again following positive Phase I results in advanced hematological malignancies for AG-221.
You may also be interested in...
Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.